S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
pixel
Log in
NASDAQ:APTO

Aptose Biosciences Price Target, Predictions & Analyst Ratings

$4.40
+0.01 (+0.23 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.33
Now: $4.40
$4.52
50-Day Range
$4.03
MA: $4.75
$7.02
52-Week Range
$3.92
Now: $4.40
$9.25
Volume707,737 shs
Average Volume993,975 shs
Market Capitalization$390.90 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62

Analyst Ratings

Aptose Biosciences (NASDAQ:APTO) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Aptose Biosciences in the last 12 months. Their average twelve-month price target is $11.29, predicting that the stock has a possible upside of 156.49%. The high price target for APTO is $16.00 and the low price target for APTO is $9.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
APTO Consensus Rating: BuyBuyBuyBuy
APTO Consensus Rating Score: 3.003.003.003.00
APTO Analyst Ratings: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
APTO Consensus Price Target: $11.29$11.29$11.50$11.40
APTO Price Target Upside: 156.49% upside77.81% upside68.09% upside62.12% upside

Aptose Biosciences (NASDAQ:APTO) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Aptose Biosciences (NASDAQ:APTO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/20/2020Canaccord GenuityReiterated RatingBuy$13.00High
10/19/2020Cantor FitzgeraldInitiated CoverageOverweight$10.00High
9/22/2020Alliance Global PartnersInitiated CoverageBuy$12.00High
6/23/2020Piper SandlerReiterated RatingOverweight$10.00High
6/14/2020OppenheimerInitiated CoverageBuy$9.00High
6/12/2020Maxim GroupInitiated CoverageBuy$16.00High
6/12/2020HC WainwrightReiterated RatingBuy$9.00Medium
5/23/2019Roth CapitalReiterated RatingBuyHigh
3/1/2019Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$6.00Medium
1/25/2019CitigroupInitiated CoverageOutperform$6.00High
11/16/2018B. RileyInitiated CoverageBuy ➝ Buy$5.00High
(Data available from 1/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.